Eagle Pharmaceuticals, Inc.
EGRX
EGRX was delisted on the 2nd of October, 2024.
182 hedge funds and large institutions have $567M invested in Eagle Pharmaceuticals, Inc. in 2018 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 71 increasing their positions, 53 reducing their positions, and 34 closing their positions.
34% more repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 53
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
4% less funds holding
Funds holding: 189 → 182 (-7)
21% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 34
47% less capital invested
Capital invested by funds: $1.07B → $567M (-$501M)
48% less call options, than puts
Call options by funds: $3.18M | Put options by funds: $6.12M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PWAM
Park West Asset Management
San Francisco,
California
|
+$15.9M |
| 2 |
Millennium Management
New York
|
+$14.1M |
| 3 |
WG
Winton Group
London,
United Kingdom
|
+$12.2M |
| 4 |
D.E. Shaw & Co
New York
|
+$8.07M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$5.74M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IAM
Iridian Asset Management
Westport,
Connecticut
|
-$64.9M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
-$26.1M |
| 3 |
First Eagle Investment Management
New York
|
-$14.8M |
| 4 |
GIP
Granite Investment Partners
El Segundo,
California
|
-$14.4M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$13.3M |
EGRX Hedge Fund Activity: Q4 2018 in Review
182 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q4 2018, worth a combined $567M — down 47% from $1.07B a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of EGRX and 27 opened new positions — a net loss of 7 holders — while 53 trimmed existing stakes and 71 added.
The largest buyer was Park West Asset Management, adding an estimated $15.9M. The largest seller was Iridian Asset Management, exiting entirely with an estimated $64.9M sold.
- 182 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q4 2018, down from 189 in Q3 2018.
- Funds reported $567M of Eagle Pharmaceuticals, Inc. stock for Q4 2018, down 47% quarter-over-quarter.
- 27 funds opened new Eagle Pharmaceuticals, Inc. positions in Q4 2018 and 34 closed out, a net change of -7 holders.
- The largest Eagle Pharmaceuticals, Inc. buyer in Q4 2018 was Park West Asset Management, an estimated $15.9M added.
- The largest Eagle Pharmaceuticals, Inc. seller in Q4 2018 was Iridian Asset Management, an estimated $64.9M sold.
Based on aggregated 13F filings for Q4 2018.